TAR 002
Alternative Names: TAR-002Latest Information Update: 24 Jun 2022
At a glance
- Originator TargImmune Therapeutics
- Class Antineoplastics; Polyethylene glycols; RNA
- Mechanism of Action Apoptosis stimulants; Cytokine stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 21 Jun 2022 TargImmune therapeutics has patent (related to the RNA polyplexes) protection in the US, Japan, Russia and Australia and patent pending in Brazil, Canada, China, Singapore, New Zealand, Mexico, Morocco, Israel, Philippines and South Africa
- 15 Jun 2022 Preclinical trials in Solid tumours in Switzerland (Parenteral) (TargImmune Therapeutics pipeline, June 2022)